Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Total Liabilities : ¥1,704 Mil (As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Total Liabilities?

Shenzhenlubris Pharmaceuticals Co's Total Liabilities for the quarter that ended in Mar. 2025 was ¥1,704 Mil.

Shenzhenlubris Pharmaceuticals Co's quarterly Total Liabilities increased from Sep. 2024 (¥1,587.94 Mil) to Dec. 2024 (¥1,713.29 Mil) but then declined from Dec. 2024 (¥1,713.29 Mil) to Mar. 2025 (¥1,704.01 Mil).

Shenzhenlubris Pharmaceuticals Co's annual Total Liabilities declined from Dec. 2022 (¥1,778.58 Mil) to Dec. 2023 (¥1,341.25 Mil) but then increased from Dec. 2023 (¥1,341.25 Mil) to Dec. 2024 (¥1,713.29 Mil).

Shenzhenlubris Pharmaceuticals Co Total Liabilities Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Total Liabilities Chart

Shenzhenlubris Pharmaceuticals Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

1,342.17

1,198.24

1,778.58

1,341.25

1,713.29

Shenzhenlubris Pharmaceuticals Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															1,347.80	1,768.67	1,587.94	1,713.29	1,704.01

Shenzhenlubris Pharmaceuticals Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shenzhenlubris Pharmaceuticals Co's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1112.967	+	(4.175	+	596.145
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,713

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	10465.604	-	8752.316
	=	1,713

Shenzhenlubris Pharmaceuticals Co's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1110.265	+	(3.14	+	590.607
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,704

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	10663.718	-	8959.706
	=	1,704

Shenzhenlubris Pharmaceuticals Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhenlubris Pharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 6009 Shennan Road, 37th Floor, Main Building, Chegongmiao Lvjing Plaza, Futian District, Guangdong, Shenzhen, CHN, 518040

Website

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.

Executives

Yan Jie	Directors, executives
Yang Jian Feng	Secretary, Director
Zhao Song Ping	Executives
Liu Jun	Executives
Li Ai Zhen	Supervisors
Chen Ping	Executives
Ye Cheng Hai	Director
Lu Feng	Executives, directors
Chen Qiong Xing	Supervisors
Li Ying Hui	Supervisors
Pan Ling Man	Independent director
Zhang Zhong Xing	Executives

Shenzhenlubris Pharmaceuticals Co Headlines

No Headlines